Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).

International journal of oncology - 1 Apr 2026

Wan Mengdi, Wang Xi, Luo Bin, Hong Huangming, Zhu Yizhun, Lin Tongyu

Abstract excerpt

Diffuse large B‑cell lymphoma (DLBCL), the most prevalent subtype of lymphoma, is characterized by rapid growth and a poor prognosis, with the R‑CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) being the standard first‑line therapy. However, 30‑40% of patients experience early relapse or refractoriness to treatment, highlighting the need to understand the mechanisms of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Lymphoma, Large B-Cell, Diffuse

Share to Prednisone

Share to Rituximab

Share to Tumor Microenvironment

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 41789584
DOI: 10.3892/ijo.2026.5859
PMCID: PMC12954847

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).PMID 41789584Read ↗

Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy ResistanceSemantic proximity Read ↗

Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.Semantic proximity Read ↗

Molecular pathogenesis of diffuse large B-cell lymphoma.Semantic proximity Read ↗

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistanceSemantic proximity Read ↗

Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Genetic Events Inhibiting Apoptosis in Diffuse Large B-cell LymphomaSemantic proximity Read ↗

Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell LymphomaSemantic proximity Read ↗

Management of Drug Resistance in Mantle Cell LymphomaSemantic proximity Read ↗

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read ↗

Unraveling MCL biology to understand resistance and identify vulnerabilitiesSemantic proximity Read ↗

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachSemantic proximity Read ↗

Altered pathways and targeted therapy in double hit lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.